Reactome | Translesion Synthesis by POLH

Translesion Synthesis by POLH

Stable Identifier

R-HSA-110320

Type

Pathway

Species

Homo sapiens

Compartment

nucleoplasm

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this pathway in the Pathway Browser

DNA polymerase eta (POLH) consists of 713 amino acids and can bypass thymidine-thymidine dimers, correctly adding two dAMPs opposite to the lesion. Mutations in the POLH gene result in the loss of this bypass activity and account for the XP variant phenotype (XPV) in human xeroderma pigmentosum disorder patients. POLH can carry out TLS past various UV and chemically induced lesions via two steps: (a) preferential incorporation of correct bases opposite to the lesion (b) conditional elongation only at the sites where such correct bases are inserted (Masutani et al. 1999, Masutani et al. 2000).

Literature References

PubMed ID	Title	Journal	Year
10369688	Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity. Masutani, C, Araki, M, Yamada, A, Kusumoto, R, Nogimori, T, Maekawa, T, Iwai, S, Hanaoka, F	EMBO J	1999
10856253	Mechanisms of accurate translesion synthesis by human DNA polymerase eta. Masutani, C, Kusumoto, R, Iwai, S, Hanaoka, F	EMBO J	2000